BriaCell Therapeutics (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, recently announced that a manuscript highlighting the company’s lead product candidate, Bria-IMT™, was published in Frontiers in Immunology. The manuscript describes the novel mechanism of action of Bria-IMT™ as well as encouraging clinical results observed in current and past clinical testing, including the notable reduction of tumor size in some patients with advanced metastatic breast cancer. The publication provides evidence for the unique immune-enhancing activity, which is believed to set the Bria-IMT™ approach apart from comparable therapies. “Our investigations into the mechanism of action of Bria-IMT™, addressed in the paper, support our hypothesis that direct activation of T cells by Bria-IMT™ is an important factor that contributes to the substantial tumor shrinkage we have seen in patients in whom HLA‑Class II molecules match with Bria-IMT™,” BriaCell President and CEO Dr. Williams stated in the news release.
To view the full press release, visit http://nnw.fm/t7K6F
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer. Immunotherapy has come to the forefront in the fight against cancer, harnessing the body’s own immune system in recognizing and selectively destroying cancer cells while sparing normal ones. Immunotherapy, in addition to generally being more targeted and less toxic than commonly used types of chemotherapy, is also thought to be a potent approach with the potential to prevent cancer recurrence. For more information, visit the company’s website at www.briacell.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
